Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Prexasertib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 known ✓ | O14757 | 18/20 | 0.90 |
| ▸ | CHEK2 known ✓ | O96017 | 1/20 | 0.90 |
| ▸ | KCNH2 | Q12809 | 15/20 | 0.90 |
| ▸ | NUAK1 | O60285 | 1/20 | 0.90 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.90 |
| ▸ | FLT3 | P36888 | 1/20 | 0.90 |
| ▸ | BLK | P51451 | 1/20 | 0.90 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.90 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.90 |
| ▸ | PRKAB1 | Q9Y478 | 1/20 | 0.90 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Prexasertib SCHEMBL1971724 | 1.00 | CHEK1 (0.90) | CHEK1KCNH2NUAK1CHEK2RPS6KB1 | |
| Prexasertib SCHEMBL30093159 | 1.00 | CHEK1 (0.90) | CHEK1KCNH2NUAK1CHEK2RPS6KB1 | |
| Prexasertib SCHEMBL14694004 | 1.00 | CHEK1 (0.90) | CHEK1KCNH2NUAK1CHEK2RPS6KB1 | |
| Prexasertib SCHEMBL30469104 | 1.00 | CHEK1 (0.90) | CHEK1KCNH2NUAK1CHEK2RPS6KB1 | |
| Prexasertib SCHEMBL20591301 | 1.00 | CHEK1 (0.90) | CHEK1KCNH2NUAK1CHEK2RPS6KB1 | |
| Prexasertib SCHEMBL30517001 | 0.95 | CHEK1 (1.00) | CHEK1KCNH2NUAK1CHEK2RPS6KB1 | |
| Prexasertib SCHEMBL29371799 | 0.95 | CHEK1 (1.00) | CHEK1KCNH2NUAK1CHEK2RPS6KB1 | |
| Prexasertib SCHEMBL1975451 | 0.95 | CHEK1 (1.00) | CHEK1KCNH2NUAK1CHEK2RPS6KB1 | |
| Prexasertib SCHEMBL30528862 | 0.95 | CHEK1 (1.00) | CHEK1KCNH2NUAK1CHEK2RPS6KB1 | |
| Prexasertib SCHEMBL20668254 | 0.94 | CHEK1 (0.98) | CHEK1KCNH2NUAK1CHEK2RPS6KB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12558345-B2 | CHK1/2 inhibitors for use in the treatment of neuroblastomas and/or soft tissue sarcomas | ELI LILLY AND COMPANY (US) | 2026-02-24 | — | — | US | claimed |
| US-20220378745-A1 | CHK1/2 INHIBITORS FOR USE IN THE TREATMENT OF NEUROBLASTOMAS AND/OR SOFT TISSUE SARCOMAS | ELI LILLY AND COMPANY | 2022-12-01 | — | — | US | claimed |
| US-12558345-B2 | CHK1/2 inhibitors for use in the treatment of neuroblastomas and/or soft tissue sarcomas | ELI LILLY AND COMPANY (US) | 2026-02-24 | — | — | US | disclosed |
| US-20220378745-A1 | CHK1/2 INHIBITORS FOR USE IN THE TREATMENT OF NEUROBLASTOMAS AND/OR SOFT TISSUE SARCOMAS | ELI LILLY AND COMPANY | 2022-12-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220378745-A1 | CHK1/2 INHIBITORS FOR USE IN THE TREATMENT OF NEUROBLASTOMAS AND/OR SOFT TISSUE SARCOMAS | CHEK1, CHEK2, PLK1 | CHEK1 1/4885CHEK2 2/4885KCNH2 3382/4885 |
| US-12558345-B2 | CHK1/2 inhibitors for use in the treatment of neuroblastomas and/or soft tissue sarcomas | CHEK1, CHEK2, MRE11 | CHEK1 1/4885CHEK2 2/4885KCNH2 3998/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.